Regulatory approval

Published by the Health Service Executive.

The Republic of Ireland's Health Service Executive (HSE) has approved cyclophosphamide in combination with prednisolone and vincristine for reimbursement as a treatment option for the first line treatment of patients with low grade B cell Non Hodgkin's Lymphoma (NHL). The regimen states that rituximab is to be included for the treatment of CD20 positive patients.

This is written in the approval document as:

First line treatment of patients with low grade B cell Non Hodgkin's lymphoma (NHL). Rituximab to be included in CD20 positive patients.

Citation

riTUXimab, Cyclophosphamide, vinCRIStine and prednisoLONE R-CVP Therapy-21 days, 2023, version number 3a, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://assets.hse.ie/media/documents/293_v3a_R_CVP.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
HSE (1)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Prednisolone, Rituximab, Vincristine